Item type:Thesis, Open Access

Chromogranin A als bedeutender Faktor für die Einschätzung der Tumorlast, der Prognose sowie der Überlebenszeit von Patienten mit metastasierten gut differenzierten neuroendokrinen Tumoren.

Thumbnail Image

Files

daw.pdf (3.39 MB)

Date

2008-07-16

relationships.isAuthorOf

Publisher

Philipps-Universität Marburg
DOI

item.page.supervisor-of-thesis

Abstract

BACKGROUND & AIMS: The prognostic role of plasma chromogranin A in patients with neuroendocrine tumors is unclear. We investigated the role of chromogranin A in predicting survival and hypothesized that chromogranin A mirrors tumor burden and that a rapid increase after a phase of stable plasma chromogranin A levels might predict exploding tumor growth. METHODS: Three hundred forty-four patients with metastatic, well-differentiated neuroendocrine tumors were included. A subsample of 102 patients was investigated to correlate radiologically classified tumor burden with plasma chromogranin A. Hepatic tumor burden (0%, 0%-25%, 25%-50%, >50%) was assessed from computed tomography/magnetic resonance imaging scans. Follow-up information until death was generated in regular intervals. RESULTS: Plasma chromogranin A levels (U/L) vary between tumor entities (Kruskal-Wallis, P < .001) and were associated with survival time (hazard ratio [hours], 2.14 per one unit in the log(10) CgA level scale; 95% confidence interval [CI], 1.75-2.62; P < .001). Chromogranin A levels correlated with hepatic tumor burden (Spearman P = .57; 95% CI, 0.44-0.70; P < .001). Additional extrahepatic tumor load did not relevantly affect plasma chromogranin A. A sudden increase observed in individual patients was paralleled by rapid tumor progress and short survival. CONCLUSIONS: Increased plasma chromogranin A in patients with metastatic neuroendocrine tumors is predictive for shorter survival. There was a modest correlation between chromogranin A levels and hepatic tumor burden. We hypothesized further that a sudden increase in individual chromogranin A levels indicates unfavorable outcome.

Review

Metadata

Contributors
Supervisor:
Dates
Created: 2008Issued: 2008-07-16Updated: 2011-08-10
DOI
https://doi.org/10.17192/z2008.0538
Faculty
Medizin
Publisher
Philipps-Universität Marburg
Language
ger
Data types
DoctoralThesis
Keywords
Gastroenteropankreatischer TumorHepatische TumorlastGastroenteropancreatic tumorHepatic tumor burden
DFG-subjects
Chromogranin ANeuroendokriner TumorTumormarker
DDC-Numbers
610
License
https://rightsstatements.org/vocab/InC-NC/1.0/
URI
https://open.uni-marburg.de/handle/10.17192/z2008.0538
show more
Wilke, Alexandra (135800978): Chromogranin A als bedeutender Faktor für die Einschätzung der Tumorlast, der Prognose sowie der Überlebenszeit von Patienten mit metastasierten gut differenzierten neuroendokrinen Tumoren.. : Philipps-Universität Marburg 2008-07-16. DOI: https://doi.org/10.17192/z2008.0538.

License

item.page.license.under-copyright
This item has been published with the following license: In Copyright